Magnetic resonance imaging (MRI) has evolved far beyond its early role as a secondary imaging tool and now stands as a cornerstone for evaluating structural heart disease. For patients with suspected or known heart valve disorders, MRI offers unmatched soft‑tissue contrast, functional quantification, and three‑dimensional anatomical detail—all without ionizing radiation. This article explores how cardiovascular MRI (CMR) is used to diagnose, characterize, and guide the management of heart valve diseases, from initial detection through long‑term follow‑up.

Understanding Heart Valve Diseases

Heart valve diseases occur when one or more of the four cardiac valves—aortic, mitral, pulmonary, and tricuspid—fail to open completely (stenosis) or close properly (regurgitation). These mechanical failures disrupt normal hemodynamics, leading to pressure overload, volume overload, or both. Over time, the heart compensates through remodeling, but untreated valve disease can progress to heart failure, arrhythmias, and increased mortality.

The most common valvular lesions in developed countries are aortic stenosis and mitral regurgitation, while rheumatic heart disease remains a leading cause of valve dysfunction in low‑ and middle‑income nations. Accurate diagnosis and severity grading are critical because treatment decisions—surgical repair, replacement, or transcatheter intervention—hinge on precise anatomical and functional assessment.

Why MRI for Valve Disease? A Complementary Tool

Echocardiography, particularly transesophageal echocardiography (TEE), is the first‑line imaging modality for valve disease due to its wide availability and real‑time capability. However, MRI provides distinct advantages that make it indispensable in complex cases:

  • Superior soft‑tissue characterization – CMR can identify myocardial fibrosis, infarction, and inflammation that accompany valve disease, information that echocardiography cannot reliably provide.
  • Unrestricted acoustic windows – Obesity, lung disease, or chest wall deformities degrade echocardiographic images but do not affect MRI quality.
  • Comprehensive flow quantification – Phase‑contrast velocity mapping directly measures transvalvular velocities, regurgitant volumes, and shunt fractions with high reproducibility.
  • Three‑dimensional volumetric data – CMR offers accurate left‑ and right‑ventricular volumes, ejection fraction, and mass without geometric assumptions.

Because of these strengths, cardiovascular MRI is increasingly used as a problem‑solving tool when echocardiographic results are discordant or inadequate, and as a gold standard for research trials.

MRI Sequences Used in Valve Assessment

A modern valve‑dedicated CMR protocol typically includes several pulse sequences, each tailored to answer specific clinical questions.

Cine Steady‑State Free Precession (SSFP)

This sequence provides high‑contrast, real‑time movies of the beating heart. Cine SSFP allows direct visualization of valve leaflets, mobility, coaptation, and the presence of prolapse or restricted motion. For example, in mitral regurgitation, cine images can reveal a flail leaflet or annular dilation. In aortic stenosis, cine shows reduced leaflet excursion and often a domed appearance.

Phase‑Contrast Velocity Mapping

Phase‑contrast (PC) MRI measures blood velocity through a specified imaging plane. By placing the plane perpendicular to the valve orifice or great vessel, clinicians can derive peak velocity, mean gradient, forward volume, and regurgitant volume. This technique is particularly valuable for quantifying aortic and pulmonary regurgitation, as well as for calculating regurgitant fraction—a key parameter for timing intervention in chronic regurgitant lesions.

Late Gadolinium Enhancement (LGE)

After injection of gadolinium‑based contrast, areas of myocardial fibrosis or scarring appear bright on LGE images. In valve disease, LGE can detect replacement fibrosis due to chronic volume or pressure overload. The extent of LGE has prognostic significance in aortic stenosis and mitral regurgitation and can influence decisions about the timing of valve surgery, especially in asymptomatic patients.

T1 and T2 Mapping

More advanced tissue characterization includes native T1 and extracellular volume (ECV) fraction measurement. These techniques quantify diffuse fibrosis without needing a reference region. Elevated ECV in aortic stenosis, for instance, correlates with adverse left ventricular remodeling and predicts postoperative outcomes.

MRI in Specific Valve Lesions

Aortic Stenosis

In aortic stenosis (AS), CMR adds value beyond echocardiography in several ways. First, cine imaging can assess valve morphology—bicuspid versus tricuspid. Second, phase‑contrast imaging through the aortic valve yields peak velocities and mean gradients; although echocardiographic Doppler remains standard, CMR gradients correlate well and are useful when acoustic windows are poor. Third, CMR excels at measuring left ventricular mass and concentric remodeling, which are important markers of disease severity and prognosis. Finally, LGE detected in the left ventricle of AS patients indicates irreversible myocardial damage and carries a higher risk for heart failure and death, even after valve replacement.

Mitral Regurgitation

Chronic mitral regurgitation (MR) places a volume load on the left ventricle. CMR is the most accurate noninvasive method for quantifying regurgitant volume and fraction. By comparing left ventricular stroke volume (from SSFP) with aortic forward flow (from PC), the regurgitant volume is derived. A regurgitant fraction greater than 50% is considered severe. CMR also helps define valve morphology, detect mitral valve prolapse, and identify associated mitral annular disjunction—a condition increasingly linked to ventricular arrhythmias. The presence of LGE in the papillary muscles or inferolateral wall can further risk‑stratify patients.

Aortic Regurgitation

Similar to MR, CMR provides precise quantification of aortic regurgitation (AR) severity. Regurgitant fraction, combined with left ventricular end‑diastolic volume index, guides timing of surgery. A regurgitant fraction ≥33% or a left ventricular end‑diastolic volume index ≥123 mL/m² in men (or ≥96 mL/m² in women) are thresholds associated with worse outcomes. Cine images also visualize the aortic root and ascending aorta, detecting aneurysm or dissection that may accompany bicuspid valve disease.

Tricuspid and Pulmonary Valve Disease

Right‑sided valve lesions are less common but often poorly assessed by echocardiography due to limited windows. CMR’s ability to measure right ventricular volumes and function, as well as quantify regurgitant flow through the pulmonic or tricuspid valve, makes it the modality of choice. In congenital heart disease patients with repaired tetralogy of Fallot, CMR is routinely used to follow pulmonary regurgitation and guide timing of pulmonary valve replacement.

Role of MRI in Managing Heart Valve Disease

Guiding Surgical and Transcatheter Interventions

Pre‑procedural planning for aortic valve replacement—whether surgical or transcatheter (TAVR)—increasingly relies on CMR. CMR provides accurate annular dimensions, coronary artery heights, and aortic root anatomy. Although CT remains the standard for TAVR sizing because of better calcium visualization, CMR can serve as an alternative when iodinated contrast is contraindicated. For mitral valve repair, CMR helps define leaflet pathology and annular geometry, and can simulate leaflet coaptation after repair.

Stratifying Asymptomatic Patients

One of the most challenging decisions in valvular heart disease is when to operate on an asymptomatic patient with severe regurgitation or stenosis. Current guidelines use echocardiographic parameters and stress testing, but CMR data are increasingly integrated. For example, in chronic aortic regurgitation, a left ventricular end‑systolic diameter >50 mm or reduced global longitudinal strain on CMR may indicate early decompensation. In mitral regurgitation, a regurgitant fraction >40% or the presence of LGE pushes toward earlier intervention.

Monitoring After Intervention

Following valve repair or replacement, CMR can assess ventricular remodeling—a reduction in left ventricular volumes or mass indicates a favorable response. It also detects complications such as prosthetic valve dysfunction (paravalvular leak, pannus formation) or new‑onset myocardial fibrosis. For patients with bioprosthetic valves, CMR may show early degenerative changes before they become hemodynamically significant.

Comparative Effectiveness: MRI vs. Echocardiography vs. CT

No single imaging modality is perfect. The following comparison highlights when CMR is most useful:

  • Echocardiography – Real‑time, portable, excellent for valve morphology and Doppler gradients; limited by windows and operator dependence.
  • CT – Superior for coronary anatomy, calcium scoring, and prosthetic valve sizing; involves ionizing radiation and iodinated contrast.
  • MRI – Best for flow quantification, myocardial tissue characterization, and ventricular volumes; no radiation; longer scan time and contraindications (pacemakers, severe claustrophobia).

In practice, CMR is often used as a complement when echocardiography is inconclusive or when additional tissue characterization is needed—for instance, to differentiate severe mitral regurgitation from cardiomyopathy where the regurgitation is secondary to ventricular dilation.

Emerging Techniques and Future Directions

4D Flow MRI

Four‑dimensional flow MRI acquires velocity data in three spatial dimensions over time. This allows visualization of complex blood flow patterns through the heart and great vessels—such as helical flow in the ascending aorta of bicuspid valve patients. 4D flow can quantify wall shear stress and turbulent kinetic energy, which may predict aortic dilation and dissection risk. Although still primarily a research tool, it is moving toward clinical use.

Strain Imaging by MRI

Feature‑tracking CMR can derive myocardial strain parameters (global longitudinal, circumferential, radial) from routine cine images. Impaired strain often precedes ejection fraction decline, offering early markers of ventricular decompensation in valve disease.

Artificial Intelligence Integration

Machine learning algorithms are being developed to automate valve segmentation, flow quantification, and detection of LGE. These tools could reduce inter‑observer variability and speed up reporting, making CMR more accessible for routine valve assessment.

Practical Considerations and Limitations

Despite its strengths, MRI is not universally available, and scan time (typically 45–60 minutes) can be challenging for dyspneic patients. Gadolinium‑based contrast is contraindicated in advanced kidney disease (eGFR <30 mL/min/1.73 m²) due to the risk of nephrogenic systemic fibrosis. Metallic implants, including some older pacemaker leads, remain absolute contraindications, though MRI‑conditional devices are now common.

Furthermore, CMR cannot visualize calcification well, which is important for aortic stenosis severity grading. In such cases, echocardiography or CT is necessary.

Conclusion

Cardiovascular MRI has matured into an essential tool in the diagnosis and management of heart valve diseases. Its ability to provide precise quantification of regurgitation and stenosis, combined with unparalleled myocardial tissue characterization, allows clinicians to make more informed decisions—especially in challenging cases where echocardiography is insufficient. As 4D flow, tissue mapping, and AI‑assisted analysis become routine, MRI will likely play an even larger role in both clinical care and research. For patients with valvular heart disease, incorporating CMR into the diagnostic pathway improves accuracy, risk stratification, and ultimately, outcomes.

References and further reading: